[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356881-105":59,"doc-detail-356881-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","e-4-4-acrylamidophenoxy-n-methylpicolinamides-as-b-rafvegfr-2-inhibitors-with-antiangiogenic-activity-in-huvec-and-zebrafish-model","(E)-4-(4-Acrylamidophenoxy)-N-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model","","Pharmacophore hybridization is applied to design (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide derivatives by combining sorafenib structural elements with cinnamide pharmacophores, followed by synthesis and biological evaluation. Antiproliferative effects are tested on A549, DU-145, SKOV3 and HepG2 cells, plus non-cancerous Hek293T cells, showing selective activity toward HepG2. Compound 5f emerges as the lead, matching sorafenib potency and demonstrating dual b-Raf and VEGFR-2 enzyme inhibition. It suppresses angiogenesis in vitro (HUVEC tube formation) and in vivo using Tg(fli1a:EGFP) zebrafish, while mechanistic studies link its effects to apoptosis via mitochondrial depolarization and ROS generation. Docking further supports binding through hydrogen-bond interactions with catalytically active residues.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/e-4-4-acrylamidophenoxy-n-methylpicolinamides-as-b-rafvegfr-2-inhibitors-with-antiangiogenic-activity-in-huvec-and-zebrafish-model/356881/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/e-4-4-acrylamidophenoxy-n-methylpicolinamides-as-b-rafvegfr-2-inhibitors-with-antiangiogenic-activity-in-huvec-and-zebrafish-model/356881.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were the (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide derivatives designed in the study?","Question",{"text":112,"@type":113},"They were rationally designed using pharmacophore hybridization by combining key structural features of sorafenib with cinnamide pharmacophores, then synthesized for evaluation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which compound was identified as the lead candidate and what were its key potency results?",{"text":117,"@type":113},"Compound 5f was identified as the lead. It showed an IC50 of 5.3 µM against HepG2 cells and inhibited b-Raf and VEGFR-2 with IC50 values of 1.45 µM and 0.37 µM, respectively.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports antiangiogenic activity for compound 5f?",{"text":121,"@type":113},"Antiangiogenic effects were shown using a tube formation assay with HUVECs in vitro and suppression of angiogenesis in transgenic zebrafish Tg(fli1a:EGFP) models in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356881,1790185715,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \n(E)-4-(4-Acrylamidophenoxy)-N-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model  \nGanga Reddy Velma 1,2,3, Srinivasa Reddy Telukutla 1,4, *, Jayaram Vankudoth 5, Ajmer Singh Grewal 6, Steven Privér 1, Poornachandra Yedla 3, Ravikumar Akunuri 3, Donald Wlodkowic 7, Srihari Pabbaraja 2,3, Suresh K. Bhargava 1, Magdalena Plebanski 4, * and Ahmed Kamal 2,3,8, *  \nAcademic Editor: Keykavous Parang  \nReceived: 12 February 2026  \nRevised: 11 May 2026  \nAccepted: 15 May 2026  \nPublished: 20 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Centre for Advanced Materials & Industrial Chemistry (CAMIC), School of Science, RMIT University, GPO BOX 2476, Melbourne, VIC 3001, Australia; [velmagangareddy47@gmail.com](velmagangareddy47@gmail.com) (G.R.V.)  \n2 Academy of Scientific and Innovative Research (AcSIR), Anusandhan Bhawan, 2-Rafi Marg, New Delhi 110 001, India  \n3 Department of Organic Synthesis & Process Chemistry, CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad 500 007, India  \n4 Accelerator for Translational Research in Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, STEM College, RMIT University, Melbourne, VIC 3083, Australia  \n5 Department of Biochemistry, Chemical Synthesis Core Facility, Albert Einstein College of Medicine, Gruss MRRC-314, Bronx, NY 10461, USA  \n6 Department of Pharmaceutical Sciences, Guru Gobind Singh College of Pharmacy, Yamuna Nagar 135 001, India  \n7 Phenomics Laboratory, School of Science, RMIT University, Plenty Road, P.O. Box 71, Bundoora, VIC 3083, Australia  \n8 Department of Chemistry, Osmania University, Hyderabad 500 007, India  \n* Correspondence: [srinivasareddy.telukutla@rmit.edu.au](srinivasareddy.telukutla@rmit.edu.au) (S.R.T.); [magdalena.plebanski@rmit.edu.au](magdalena.plebanski@rmit.edu.au) (M.P.); [ahmedkamal@osmania.ac.in](ahmedkamal@osmania.ac.in) (A.K.)  \nAbstract  \nPharmacophore hybridization is a well-established strategy for developing novel anticancer agents with improved biological profiles. In this study, a new series of (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide derivatives has been rationally designed by hybridizing key structural features of sorafenib with cinnamide pharmacophores and subsequently synthesized. The antiproliferative activities of the synthesized compounds were evaluated against a panel of human cancer cell lines, including A549 (lung), DU-145 (prostate), SKOV3 (ovarian), and HepG2 (liver), along with non-cancerous Hek293T cells. In comparison with the standard drug sorafenib, most of the (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamides demonstrated significant antiproliferative activity, with specificity toward the HepG2 (liver cancer) cell line, and no effect on the noncancerous cells (Hek293T) . Among them, compound 5f, the derivative containing a trifluoromethyl-substituted cinnamoyl moiety was identified as the lead candidate, exhibiting an IC 50 of 5.3 µM towards HepG2 (liver) cancer cells, comparable to the reference drug sorafenib. Enzyme inhibition studies showed that compound 5f inhibited both b-Raf and VEGFR-2 with IC50 values of 1.45 and 0.37 µM, respectively. Furthermore, compound 5f suppressed angiogenesis in vitro and in vivo, as evidenced by the tube formation assay using HUVECs and in transgenic zebrafish Tg(fli1a:EGFP) models, respectively. Mechanistic studies indicated that compound 5f induced apoptosis in HepG2 cells through mitochondrial membrane depolarization and increased ROS generation. Molecular docking studies supported experimental findingsand showed that 5f can interact with catalytically active residues via hydrogen-bonding interactions. Overall, these results highlight the potential of compound 5f as a promising dual target therapeutic lead with dual di","cbCaib9mqUdzOl69","https://ap.wps.com/l/cbCaib9mqUdzOl69","pdf",6902711,25,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"How were the (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide derivatives designed in the study?\",\"answer\":\"They were rationally designed using pharmacophore hybridization by combining key structural features of sorafenib with cinnamide pharmacophores, then synthesized for evaluation.\"},{\"question\":\"Which compound was identified as the lead candidate and what were its key potency results?\",\"answer\":\"Compound 5f was identified as the lead. It showed an IC50 of 5.3 µM against HepG2 cells and inhibited b-Raf and VEGFR-2 with IC50 values of 1.45 µM and 0.37 µM, respectively.\"},{\"question\":\"What evidence supports antiangiogenic activity for compound 5f?\",\"answer\":\"Antiangiogenic effects were shown using a tube formation assay with HUVECs in vitro and suppression of angiogenesis in transgenic zebrafish Tg(fli1a:EGFP) models in vivo.\"}]","(E)-4-(4-Acrylamidophenoxy)-N-Methylpicolinamides as b-Raf/VEGFR-2 Inhibitors with Antiangiogenic Activity in HUVEC and Zebrafish Model | PDF",1790127893,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33e81582c2d18edd3b46567f70cedb9d.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d407044e2294bc27ef593a981edfd61d.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27b804efe111c19697485f536cd42dff.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66599365a2916b3f1a34d331086d18f3.webp",980,1385]